NasdaqCM - Nasdaq Real Time Price USD

Indaptus Therapeutics, Inc. (INDP)

Compare
0.9380 +0.0480 (+5.39%)
At close: December 20 at 4:00:02 PM EST
0.9399 +0.00 (+0.20%)
After hours: December 20 at 5:18:52 PM EST
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for INDP

Recent News: INDP

View More
Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement

Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement
GlobeNewswire 28 days ago
Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire last month
Indaptus Therapeutics’ Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology

Indaptus Therapeutics’ Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology
GlobeNewswire last month
Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting

Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting
GlobeNewswire last month
Indaptus Therapeutics to Present at Two Upcoming Investor Conferences

Indaptus Therapeutics to Present at Two Upcoming Investor Conferences
GlobeNewswire last month
Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment Combinations

Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment Combinations
GlobeNewswire last month
Indaptus Therapeutics Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety Data

Indaptus Therapeutics Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety Data
GlobeNewswire 2 months ago
Indaptus Therapeutics Founder and Chief Scientific Officer to Speak on Lumanity Webinar about the Future of Innate Immunity in Cancer Immunotherapy

Indaptus Therapeutics Founder and Chief Scientific Officer to Speak on Lumanity Webinar about the Future of Innate Immunity in Cancer Immunotherapy
GlobeNewswire 2 months ago
Indaptus Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

Indaptus Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
GlobeNewswire 2 months ago
Indaptus Therapeutics Reports Encouraging New Safety Data for Decoy20 Clinical Program; Company Expands Enrollment of Patients on Weekly Dosing at Two Different Doses

Indaptus Therapeutics Reports Encouraging New Safety Data for Decoy20 Clinical Program; Company Expands Enrollment of Patients on Weekly Dosing at Two Different Doses
GlobeNewswire 3 months ago
Indaptus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Indaptus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
GlobeNewswire 3 months ago
View More

Related Tickers

ZIVO ZIVO Bioscience, Inc.
18.00
+2.27%
 
AKTX Akari Therapeutics, Plc
0.9700
-3.00%
 
KTTA Pasithea Therapeutics Corp.
2.6300
-1.50%
 
COEP Coeptis Therapeutics Holdings, Inc.
0.1415
-2.08%
 
ANRO Alto Neuroscience, Inc.
3.8900
+4.57%
 
EDSA Edesa Biotech, Inc.
1.7300
-1.14%
 
BCDA BioCardia, Inc.
1.9700
+7.07%
 
ACTU Actuate Therapeutics, Inc. Common stock
6.77
-3.97%
 
IPA ImmunoPrecise Antibodies Ltd.
0.4001
-4.74%
 
AZTR Azitra, Inc.
0.4150
+5.01%